Intervention Protocol

Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma

  1. Thiagarajan Shivakumar1,*,
  2. Sudhir Nair2,
  3. Tejpal Gupta3,
  4. Sadhana Kannan4

Editorial Group: Cochrane Ear, Nose and Throat Disorders Group

Published Online: 10 JAN 2014

DOI: 10.1002/14651858.CD010906

How to Cite

Shivakumar T, Nair S, Gupta T, Kannan S. Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010906. DOI: 10.1002/14651858.CD010906.

Author Information

  1. 1

    Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology (Head & Neck Services), Navi Mumbai, India

  2. 2

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology, Navi Mumbai, India

  3. 3

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Radiation Oncology, Navi Mumbai, India

  4. 4

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Clinical Research Secretariat/Epidemiology & Clinical Trial Unit, Navi Mumbai, India

*Thiagarajan Shivakumar, Surgical Oncology (Head & Neck Services), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India. drshiva78in@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 10 JAN 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objective

To assess the efficacy of a weekly cisplatin regimen compared to a three-weekly regimen, given with curative intent to treat locally advanced HNSCC, in terms of overall survival (at five years).

Secondary objective

To assess the distant metastasis-free survival (at two years), disease-free survival (at two years) and the toxicity profile of the two regimens.